Dec. 28, 2011
/PRNewswire-Asia/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (NASDAQ: CSKI), a leading fully integrated pharmaceutical company in
the People's Republic of China
("PRC"), today announced that
, the Company's Chief Financial Officer, will be leaving the Company effective
December 22, 2011
for personal reasons. His resignation was not a result of any disputes or disagreements with the Company on any matter relating to its operations, policies or practices. The Company has initiated a search for a new Chief Financial Officer and will make an announcement as soon as a candidate has been chosen.
"We truly appreciate Mr. Pan's contributions during his tenure and wish him the best in all of his future endeavors," said Mr.
, China Sky One Medical's General Manager and a Board Director.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a
corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company, the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as
or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding
and management change
Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People
s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, the potential of introduced or undetected flaws and defects in products
, consumer acceptance of new products to be launched
and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
Investor Relations Contact:
China Sky One Medical
, Corporate SecretaryEmail:
CCG Investor Relations
, Vice PresidentTel: +1-310-954-1353Email:
SOURCE China Sky One Medical, Inc.